Loading patent…
AssigneeGruenenthal GmbH
InventorsJohannes Bartholomaeus, Iris Ziegler
Estimating the term…
A delayed release pharmaceutical formulation containing 1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol or a pharmaceutically acceptable salt thereof in a matrix; said matrix containing from 1 to 80 wt. % of at least one pharmaceutically acceptable, matrix-forming, hydrophilic or hydrophobic polymer and having the following in vitro dissolution rate relative to 100 wt. % of the 1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol contained in the formulation: 3-35 wt. % released after 0.5 hour, 5-50 wt. % released after 1 hour, 10-75 wt. % released after 2 hours, 15-82 wt. % released after 3 hours, 30-97 wt. % released after 6 hours, more than 50 wt. % released after 12 hours, more than 70 wt. % released after 18 hours, and more than 80 wt. % released after 24 hours.
A delayed release pharmaceutical formulation containing:
A delayed release pharmaceutical formulation containing 1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol or a pharmaceutically acceptable salt thereof in a release-delaying matrix, said matrix comprising from 1 to 80 wt. % of at least one pharmaceutically acceptable, matrix-forming polymer, wherein said polymer comprises a cellulose ether or cellulose ester that has a viscosity of 3000 to 150,000 mPas in a 2 wt. % aqueous solution at 20° C.
A delayed release pharmaceutical formulation containing 1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol or a pharmaceutically acceptable salt thereof in a release-delaying matrix, said matrix comprising from 1 to 80 wt. % of at least one pharmaceutically acceptable, matrix-forming polymer, wherein said polymer comprises a cellulose ether or cellulose ester that has a viscosity of 3000 to 150,000 mPas in a 2 wt. % aqueous solution at 20° C.
Dependencies are inferred from the claim text.